title: The intrauterine device: a good thing revisited.
authors: Dr. Soper is from the Department of Obstetrics and Gynecology and Medicine, Division of Infectious Diseases, at the Medical University of South Carolina, Charleston, SC; e-mail: soperde@musc.edu.
authors: David E
authors: DE
authors: Soper
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D035843:Biomedical Research / Q000592:standards*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003271:Contraceptive Agents, Female / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007434:Intrauterine Devices / Q000009:adverse effects*; D007436:Intrauterine Devices, Medicated / Q000009:adverse effects*; D016912:Levonorgestrel / Q000008:administration & dosage* / Q000009:adverse effects*; D008528:Mefenamic Acid / Q000627:therapeutic use*; D008796:Metrorrhagia / Q000139:chemically induced* / Q000188:drug therapy*; D000292:Pelvic Inflammatory Disease / Q000209:etiology*; D013629:Tamoxifen / Q000627:therapeutic use*; D014148:Tranexamic Acid / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000933:Antifibrinolytic Agents; D018931:Antineoplastic Agents, Hormonal; D003271:Contraceptive Agents, Female; D013629:Tamoxifen; D008528:Mefenamic Acid; D016912:Levonorgestrel; D014148:Tranexamic Acid
references: Finer LB, Jerman J, Kavanaugh ML. Changes in use of long-acting contraceptive methods in the United States, 2007-2009. Fertil Steril 2012;98:893–7.
references: Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J; ECLIPSE Trial Collaborative Group. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013;368:128–37.
references: Sørdal T, Inki P, Draeby J, O´Flynn M, Schmelter T. Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstet Gynecol 2013;121:934–41.
references: Wong AWY, Chan SSC, Yeo W, Yu M-Y, Tam W- H. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstet Gynecol 2013;121:943–50.
references: Hubacher D, Grimes DA, Gemzell-Danielsson K. Pitfalls of research linking the intrauterine device to pelvic inflammatory disease. Obstet Gynecol 2013;121:1091–8.
references: Brown AJ, Westin SN, Braddus RR, Schmeler K. Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol 2012;119:423–6.
references: Antoniou G, Kalogirou D, Karakitsos P, Antoniou D, Kalogirou O, Giannikos L. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses. Maturitas 1997;26:103–11.
references: Darney PD. Time to pardon the IUD? N Engl J Med 2001;345:608–10.
references: Walsh T, Grimes D, Frezieres R, Nelson A, Bernstein L, Coulson A, et al.. Randomised controlled trial of prophylactic antibiotics before insertion of intrauterine devices. IUD Study Group. Lancet 1998;351:1005–8.
references: Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001;345:561–7.